Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2010

View Archived Issues

U.S. DoD funds Tekmira's development of RNAi agent against Ebola virus infection

New HIF-1-alpha activators claimed by sanofi-aventis

Ziopharm begins phase III palifosfamide trial in metastatic soft tissue sarcoma

Scientists identify NAbs with potent HIV-1 neutralization activity

Hexyl/methyl aminolevulinate photodynamic therapy does not damage cervical tissue

SRT-2104 improves metabolic function and glucose homeostasis in mice with DIO

BI-10773 is safe and tolerated in healthy subjects and in type 2 diabetes

ARC-4558 topical gel reduces pain in phase IIb trial in diabetes-associated neuropathy

KAI-4169 shows promise to treat secondary hyperparathyroidism in phase I trial

Aoxing confirms enrollment progress for phase III trial of TJSL capsules

Archer Biosciences begins dosing in third cohort of TPI-287 trial in metastatic melanoma

CytRx advances its bafetinib program in oncology

Seattle Genetics and Agensys begin phase I ASG-5ME trial in pancreatic cancer

German scientists disclose new HIF-mediated transcription inhibitors

Boehringer Ingelheim discovers new CB2 receptor agonists

Aegera reports survival data from phase I AEG-35156 combination trial

Inotek describes novel PARP inhibitors

Health Canada approves Winston Laboratories' Civanex for osteoarthritis pain

CVI Pharmaceuticals identifies novel lipid-lowering agents

Acorda Therapeutics receives NIH grant to develop GGF2 in heart failure

AiCuris presents novel anti-HIV agents

FDA accepts Mannkind's resubmission of Afrezza NDA

U.S. DoD funds AVI BioPharma's anti-Ebola and -Marburg virus research

Sepracor to change name to Sunovion Pharmaceuticals

FDA advisory committee votes for removal of first-line indication from Avastin label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...